Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U01 Substudy 01J: First-line treatment for KRAS G12C-mutant nonsquamous NSCLC
2025-521939-36-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 2, randomised trial of calderasib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Merck & Co. Primary endpoints: Dose-limiting toxicity incidence, Adverse event incidence and 2 more. Planned start Mar 2026; status: authorised.
02
Drugs
calderasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2025-521939-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521939-36-00.